Osecon announced that its subsidiary Osecon Pharmaceutical reached a licensing agreement with Arnold Pharmaceuticals to obtain exclusive rights in the development, production and commercialization of the AN9025 project within the license area. AN9025 is a novel oral pan-RAS inhibitor developed by Arnold Pharmaceuticals and is intended to treat RAS mutant solid tumors. The agreement includes 35 million head of state payments, total development and sales milestone payments of no more than 470 million yuan, and royalties are gradient fees for annual net sales. The introduction of AN9025 will strengthen the company's layout in the fields of lung cancer, gastrointestinal tumors, etc., and enhance its competitiveness in anti-tumor treatment.

Osecon announced that its subsidiary Osecon Pharmaceutical reached a licensing agreement with Arnold Pharmaceuticals to obtain exclusive rights in the development, production and commercialization of the AN9025 project within the license area. AN9025 is a novel oral pan-RAS inhibitor developed by Arnold Pharmaceuticals and is intended to treat RAS mutant solid tumors. The agreement includes 35 million head of state payments, total development and sales milestone payments of no more than 470 million yuan, and royalties are gradient fees for annual net sales. The introduction of AN9025 will strengthen the company's layout in the fields of lung cancer, gastrointestinal tumors, etc., and enhance its competitiveness in anti-tumor treatment.